scispace - formally typeset
Search or ask a question
Topic

Deferasirox

About: Deferasirox is a research topic. Over the lifetime, 1335 publications have been published within this topic receiving 28622 citations. The topic is also known as: ICL670A & ICL 670a.


Papers
More filters
Journal ArticleDOI
01 Feb 1997-Blood
TL;DR: The toxicity of this agent mandates a careful evaluation of the balance between risk and benefit of deferiprone in patients with thalassemia, in most of whom long-term deferoxamine is safe and efficacious therapy.

1,050 citations

Journal ArticleDOI
TL;DR: The early use of deferoxamine in an amount proportional to the transfusional iron load reduces the body iron burden and helps protect against diabetes mellitus, cardiac disease, and early death in patients with thalassemia major.
Abstract: Background To determine whether deferoxamine prevents the complications of transfusional iron overload in thalassemia major, we evaluated 59 patients (30 were female and 29 male; age range, 7 to 31 years) periodically for 4 to 10 years or until death. Methods At each follow-up visit, we performed a detailed clinical and laboratory evaluation and measured hepatic iron stores with a noninvasive magnetic device. Results The body iron burden as assessed by magnetic measurement of hepatic iron stores was closely correlated (R = 0.89, P<0.001) with the ratio of cumulative transfusional iron load to cumulative deferoxamine use (expressed in millimoles of iron per kilogram of body weight, in relation to grams of deferoxamine per kilogram, transformed into the natural logarithm). Each increase of one unit in the natural logarithm of the ratio (transfusional iron load to deferoxamine use) was associated with an increased risk of impaired glucose tolerance (relative risk, 19.3; 95 percent confidence interval, 4.8 to...

784 citations

Journal ArticleDOI
01 May 2006-Blood
TL;DR: A comparative phase 3 trial was conducted to demonstrate the efficacy of deferasirox in regularly transfused patients with beta-thalassemia aged 2 years or older, and found it to be a promising once-daily oral therapy for the treatment of transfusional iron overload.

660 citations

Journal ArticleDOI
01 May 2006-Blood
TL;DR: Deferiprone monotherapy was significantly more effective than deferoxamine over 1 year in improving asymptomatic myocardial siderosis in beta-thalassemia major.

446 citations

Journal ArticleDOI
26 Apr 2012-Blood
TL;DR: The National Heart, Lung, and Blood Institute closed SWiTCH after interim analysis revealed equivalent liver iron content, indicating futility for the composite primary end point.

305 citations


Network Information
Related Topics (5)
Myeloid
24.1K papers, 980.7K citations
87% related
Leukemia
54.5K papers, 1.7M citations
87% related
Haematopoiesis
35.2K papers, 1.6M citations
86% related
Bone marrow
87.5K papers, 3.1M citations
85% related
Progenitor cell
50.8K papers, 2.5M citations
83% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
202342
2022119
202146
202045
201966
201860